NJ’s Merck forges partnership to develop new medicines for asthma and other … – The Star-Ledger – NJ.com


The Star-Ledger – NJ.com

NJ's Merck forges partnership to develop new medicines for asthma and other
The Star-Ledger – NJ.com
Lycera is working on drug candidates that target two pathways, so called Th17 cells and RORyt, that play a critical role in immune-mediated diseases, including psoriasis, asthma and inflammatory bowel disease. Merck, which is based in Whitehouse
Merck and Lycera to Develop Oral Autoimmune Disease Drugs Targeting Th17 CellsGenetic Engineering News

all 13 news articles »

View full post on asthma – Google News